Synonym
Transcainide; R 54718; R-54718; R54718;
IUPAC/Chemical Name
4-(dimethylamino)-N-(2,6-dimethylphenyl)-1-((1R,2R)-2-hydroxycyclohexyl)piperidine-4-carboxamide
InChi Key
MFKCGXDCHAFQQZ-RTBURBONSA-N
InChi Code
InChI=1S/C22H35N3O2/c1-16-8-7-9-17(2)20(16)23-21(27)22(24(3)4)12-14-25(15-13-22)18-10-5-6-11-19(18)26/h7-9,18-19,26H,5-6,10-15H2,1-4H3,(H,23,27)/t18-,19-/m1/s1
SMILES Code
O=C(C1(N(C)C)CCN([C@H]2[C@H](O)CCCC2)CC1)NC3=C(C)C=CC=C3C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
373.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Carmeliet E, Janssen PA, Heykants J, Niemegeers CJ, Remeysen P, Van De Water A, Van Gerven W, Wauquier A, Xhonneux R. Electrophysiologic, antiarrhythmic and hemodynamic effects of transcainide. Arch Int Pharmacodyn Ther. 1987 Jun;287(2):272-90. PubMed PMID: 3632145.
2: Bennett PB, Stroobandt R, Kesteloot H, Hondeghem LM. Sodium channel block by a potent, new antiarrhythmic agent, transcainide, in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 1987 Jun;9(6):661-7. PubMed PMID: 2442531.
3: Yang X, Yu T, Kesteloot H. Clinical and electrophysiologic studies of R61748 (transcainide): a new class Ic antiarrhythmic drug. Acta Cardiol. 1992;47(1):43-56. PubMed PMID: 1378674.
4: Hill RJ, Thakore E, Taouis M, Duff HJ, Sheldon RS. Transcainide: biochemical evidence for state-dependent interaction with the class I antiarrhythmic drug receptor. Eur J Pharmacol. 1991 Oct 2;203(1):51-8. PubMed PMID: 1665791.
5: Zamponi GW, French RJ. Transcainide causes two modes of open-channel block with different voltage sensitivities in batrachotoxin-activated sodium channels. Biophys J. 1994 Sep;67(3):1028-39. Erratum in: Biophys J 1995 Mar;68(3):1197. PubMed PMID: 7811913; PubMed Central PMCID: PMC1225455.
6: Carmeliet E. Slowly developing activation block of cardiac sodium channels by a lidocaine analog, transcainide. J Cardiovasc Pharmacol. 1988 Jul;12(1):110-5. PubMed PMID: 2459527.
7: Stroobandt R, Bennett PB, Hondeghem LM, Kesteloot H. Evaluation of the efficacy and tolerance of the antiarrhythmic agent transcainide (R 54718). Eur J Clin Pharmacol. 1987;32(5):449-56. PubMed PMID: 2441995.
8: Iwata T, Inoue K, Nishiyama N, Izumi N, Mizuguchi S, Tsukioka T, Suehiro S. Late massive hemoptysis after transbronchial biopsy of hamartoma: an involvement of pulmonary artery and vein. Ann Thorac Cardiovasc Surg. 2007 Dec;13(6):400-2. PubMed PMID: 18292723.
9: Sheldon RS, Duff HJ, Thakore E, Hill RJ. Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels. J Pharmacol Exp Ther. 1994 Jan;268(1):187-94. PubMed PMID: 8301556.
10: Johnson N, Spinelli W, Rosen MR. Cardiac electrophysiologic effects of R 54718. Eur J Pharmacol. 1987 Mar 3;135(1):41-51. PubMed PMID: 3569425.
